Studies Addressing Rare Neurodegenerative Diseases including ALS
Funds research to develop medical products for treating or curing ALS and other rare neurodegenerative diseases in adults and children.
Funder: Food and Drug Administration
Due Dates: Forecasted; estimated application due date not yet announced
Funding Amounts: Expected 10 awards; award ceiling and total program funding not yet specified
Summary: Supports research advancing medical product development for prevention, diagnosis, mitigation, treatment, or cure of ALS and other rare neurodegenerative diseases in adults and children.
Key Information: This is a forecasted opportunity; details on deadlines and funding amounts will be updated when the official announcement is released.
Description
This forecasted funding opportunity from the Food and Drug Administration (FDA) aims to support studies that advance the development of medical products—such as drugs, biologics, or devices—intended to prevent, diagnose, mitigate, treat, or cure amyotrophic lateral sclerosis (ALS) and other rare neurodegenerative diseases in both adults and children. The FDA seeks to address critical knowledge gaps, have a significant impact on rare neurodegenerative disease research, and inform current or future product development through this initiative.
